GAM
DNLI icon

Groupama Asset Management’s Denali Therapeutics DNLI Stock Holding History

Groupama Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.91M Buy
229,939
+22,809
+11% +$469K 0.07% 98
2026
Q1 		$3.98M Buy
207,130
+55,539
+37% +$1.11M 0.06% 112
2025
Q4 		$2.5M Buy
151,591
+15,833
+12% +$267K 0.04% 144
2025
Q3 		$1.97M Sell
135,758
-39,773
-23% -$572K 0.03% 170
2025
Q2 		$2.47M Buy
175,531
+31,043
+21% +$437K 0.04% 162
2025
Q1 		$2.14M Buy
144,488
+34,281
+31% +$657K 0.04% 176
2024
Q4 		$2.23M Buy
110,207
+32,162
+41% +$823K 0.05% 185
2024
Q3 		$1.83M Buy
78,045
+5,657
+8% +$140K 0.05% 187
2024
Q2 		$1.68M Buy
72,388
+28,561
+65% +$548K 0.02% 234
2024
Q1 		$899K Buy
43,827
+8,814
+25% +$166K 0.02% 326
2023
Q4 		$752K Buy
+35,013
New +$693K 0.02% 310

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Groupama Asset Management's DNLI Position: Q2 2026 in Review

Groupama Asset Management increased its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, buying an estimated $469K and bringing the position to 229,939 shares worth $5.91M. The position accounts for 0.07% of the portfolio, ranked #98.

Groupama Asset Management first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Groupama Asset Management held 229,939 shares of Denali Therapeutics worth $5.91M as of Q2 2026.
  • Groupama Asset Management bought 22,809 Denali Therapeutics shares in Q2 2026, an estimated $469K.
  • Denali Therapeutics made up 0.07% of Groupama Asset Management's portfolio in Q2 2026, its #98 holding.
  • Groupama Asset Management first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.